<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18642" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bronchiolitis Obliterans</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krishna</surname>
            <given-names>Rachana</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anjum</surname>
            <given-names>Fatima</given-names>
          </name>
          <aff>Temple University, Lewis Katz School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oliver</surname>
            <given-names>Tony I.</given-names>
          </name>
          <aff>University Of South Dakota</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rachana Krishna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fatima Anjum declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tony Oliver declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18642.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Bronchiolitis obliterans is also known as obliterative bronchiolitis or constrictive bronchiolitis. When it occurs after lung transplantation or hematopoietic stem cell transplantation (HSCT), it is called bronchiolitis obliterans syndrome. Bronchiolitis obliterans is a type of obstructive lung disease of the small airways. This activity reviews the pathophysiology and cause of bronchiolitis obliterans and highlights the interprofessional team's role in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the risk factors for bronchiolitis obliterans.</p></list-item><list-item><p>Describe the pathophysiology of bronchiolitis obliterans.</p></list-item><list-item><p>Summarize the treatment options for bronchiolitis obliterans.</p></list-item><list-item><p>Outline the importance of improving care coordination among interprofessional team members to improve patients' outcomes affected by bronchiolitis obliterans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18642&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18642">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18642.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Bronchiolitis obliterans is also known as obliterative bronchiolitis or constrictive bronchiolitis. When it occurs after lung transplantation or hematopoietic stem cell transplantation (HSCT), it is called bronchiolitis obliterans syndrome.<xref ref-type="bibr" rid="article-18642.r1">[1]</xref><xref ref-type="bibr" rid="article-18642.r2">[2]</xref><xref ref-type="bibr" rid="article-18642.r3">[3]</xref>&#x000a0;Bronchiolitis obliterans&#x000a0;is a type of obstructive lung disease of the small airways.<xref ref-type="bibr" rid="article-18642.r4">[4]</xref> It is a rare disease with characteristic features of fibrosis of terminal and distal bronchioles and spirometry showing airflow obstruction. It usually leads to a progressive decline in lung function and has variable outcomes.</p>
      </sec>
      <sec id="article-18642.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Several risk factors can lead to the development of bronchiolitis obliterans. It is one of the most common noninfectious complications after lung transplant and hematopoietic stem cell transplantation. Other etiologies of bronchiolitis obliterans include exposure to inhaled toxins and gases, including sulfur mustard gas, nitrogen oxides, diacetyl (used as popcorn flavoring), fly ash, and fiberglass. Bronchiolitis obliterans&#x000a0;is also associated with autoimmune disorders, especially rheumatoid arthritis, SLE, and less commonly with inflammatory bowel disease. It is also known to occur after a respiratory viral infection (adenovirus, respiratory syncytial virus), especially in children. Other infections associated with bronchiolitis obliterans&#x000a0;are HIV,&#x000a0;Postinfectious (mycoplasma, bacteria, fungi), and Human Herpes Virus (HHV) 8. Rare conditions like Castleman disease and paraneoplastic pemphigus have also been associated with bronchiolitis obliterans. Other associations include microcarcinoid tumorlets and Cryptogenic constrictive bronchiolitis.</p>
      </sec>
      <sec id="article-18642.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Bronchiolitis obliterans syndrome is considered a form of chronic allograft rejection after lung transplantation. The majority of lung transplant recipients who are long term survivors develop bronchiolitis obliterans syndrome. More than 50% of recipients will develop some degree of BO by 5 years post-transplant. The average time to diagnose BO is 16 to 20 months after lung transplant but has been reported as early as 3 months after transplantation. About 5% to 14% of Hematopoietic stem cell transplantation (HSCT) recipients also develop bronchiolitis obliterans syndrome, which is pulmonary graft vs. host disease and can present several months to years later after transplantation.</p>
      </sec>
      <sec id="article-18642.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>There is inflammation of sub-epithelial structures and dysregulated repair in response to injury from inhalational toxins or autoimmune responses, leading to fibroproliferation and abnormal regeneration of epithelium of the small airways. Histopathology classically demonstrates the involvement of terminal and respiratory bronchioles (distal small airways) but without significant changes in alveolar spaces and distal lung parenchyma. Hypertrophy of the smooth muscles of the bronchioles, peribronchiolar inflammatory infiltrates, accumulation of mucus in the bronchiolar lumen, and bronchiolar scarring can be noted in bronchiolitis obliterans.<xref ref-type="bibr" rid="article-18642.r5">[5]</xref> There is a concentric narrowing of the lumen of the bronchioles by inflammatory fibrosis. There may even be complete occlusion of the lumen in some cases.</p>
        <p>In lung transplantation, microvascular insufficiency and alloimmune responses to the transplanted lung may result in airway injury and the development of bronchiolitis obliterans syndrome. Episodes of acute cellular rejection, HLA antibodies, and gastroesophageal reflux disease with microaspiration have been shown to increase the risk of developing bronchiolitis obliterans syndrome&#x000a0;after transplantation.</p>
        <p>In bronchiolitis obliterans&#x000a0;associated with paraneoplastic pemphigus, autoantibodies against desmoglein and plakin protein are found in both cutaneous and respiratory epithelium have been implicated.</p>
      </sec>
      <sec id="article-18642.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Bronchiolitis obliterans characteristically presents with dyspnea and cough that is persistent and progressive. Some may also have wheezing. Symptoms usually develop over weeks to months and are not episodic, unlike asthma. History may also elicit recent exposure to toxic fumes or gases, viral infections, symptoms of joint stiffness in cases of rheumatoid arthritis, prior lung, or hematopoietic stem cell transplantation.</p>
        <p>A physical exam may reveal decreased breath sounds and a prolonged expiratory phase with or without wheeze, usually in the inspiratory and expiratory phase. Rales may also be noted in some cases. Cases of bronchiolitis obliterans&#x000a0;associated with Castleman&#x02019;s disease may also have paraneoplastic pemphigus, which may present with oral ulcers as well as lymphadenopathy.&#x000a0;</p>
      </sec>
      <sec id="article-18642.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Pulmonary function testing is essential for diagnosis. Spirometry demonstrates airflow obstruction that does not reverse with inhaled bronchodilator challenge. Forced expiratory volume in one second (FEV1) will be reduced, and the ratio of FEV1 to forced vital capacity (FEV1/FVC) is also reduced. Hyperinflation may occur, and hence total lung capacity (TLC) may be increased with air trapping. Diffusion capacity (DLCO) is usually reduced. <xref ref-type="bibr" rid="article-18642.r1">[1]</xref><xref ref-type="bibr" rid="article-18642.r6">[6]</xref><xref ref-type="bibr" rid="article-18642.r7">[7]</xref>The degree of FEV1 decline from post-transplant value determines the stage of bronchiolitis obliterans syndrome&#x000a0;in lung transplant.</p>
        <p>Chest radiographs may be normal in early disease or show signs of hyperinflation. Chest CT imaging may show bronchial wall thickening, mosaic pattern with patchy areas of hypo attenuation. If there are dynamic images with inspiratory and expiratory films, a mosaic pattern persists due to air trapping from small airway disease.</p>
        <p>Bronchoscopy can be performed if other causes of airflow obstruction are suspected like endobronchial tumors or sarcoid but might be unrevealing in bronchiolitis obliterans. A lung biopsy is usually not necessary for diagnosis in the setting of classic symptoms, air trapping on imaging, airflow obstruction on spirometry in the setting of organ transplantation, or toxic inhalational injury. If required for diagnosis, surgical lung biopsy is preferred over transbronchial biopsy since it involves distal bronchioles and not parenchyma. Also, the sensitivity by transbronchial biopsy for the diagnosis of BO is low (range 15 to 87%). In cases following lung transplantation, a biopsy is not required to diagnose bronchiolitis obliterans syndrome&#x000a0;but may be required to exclude other causes of deterioration lung function like infection or acute rejection. Spirometry showing obstructive pattern is necessary for diagnosis.</p>
      </sec>
      <sec id="article-18642.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of bronchiolitis obliterans syndrome&#x000a0;after lung transplant involves augmenting immunosuppression since it is thought to be a form of chronic rejection. Hence, increasing or adding immunosuppressive agents like tacrolimus, cyclosporine, mycophenolate mofetil, and prednisone has been used to treat bronchiolitis obliterans syndrome&#x000a0;after transplant. Azithromycin has also been shown to decrease the incidence of bronchiolitis obliterans syndrome&#x000a0;and improvement in lung function. The combination of inhaled fluticasone, oral montelukast, and azithromycin triple therapy has also been shown to decrease the decline in lung function in bronchiolitis obliterans syndrome&#x000a0;post-HSCT. In addition to these therapies, controlling gastroesophageal reflux is also recommended to decrease bronchiolitis obliterans syndrome. In cases where bronchiolitis obliterans syndrome&#x000a0;is progressive and severe, then retransplantation of a lung may be indicated.<xref ref-type="bibr" rid="article-18642.r8">[8]</xref><xref ref-type="bibr" rid="article-18642.r9">[9]</xref><xref ref-type="bibr" rid="article-18642.r10">[10]</xref> Extracorporeal photopheresis has also been successfully used to slow the decline in lung function from bronchiolitis obliterans syndrome. In non-transplant related bronchiolitis obliterans, removal from offending agents is essential. Immunosuppression with corticosteroids and cytotoxic agents like cyclophosphamide has been used for bronchiolitis obliterans&#x000a0;related to rheumatoid arthritis but has not been beneficial for bronchiolitis obliterans&#x000a0;from toxic inhalation or post-infectious etiology. In these patients, symptomatic treatment should be provided with cough suppressants, inhaled bronchodilators, and oxygen supplementation if needed.</p>
      </sec>
      <sec id="article-18642.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Asthma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bronchogenic carcinoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bronchiectasis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cystic fibrosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Interstitial lung disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pleural effusion</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary edema</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Recurrent aspiration</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Recurrent pulmonary emboli</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tracheobronchomalacia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18642.s10" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Clinical Staging System for Bronchiolitis Obliterans Syndrome (BOS)</bold>
</p>
        <table-wrap id="article-18642.table0" position="float" orientation="portrait">
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">BOS-0</td>
                <td rowspan="1" colspan="1">No BO</td>
                <td rowspan="1" colspan="1">FEV1 &#x0003e;90% of baseline and FEF25-75% &#x0003e;75% of baseline</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">BOS 0-p</td>
                <td rowspan="1" colspan="1">Potential BO</td>
                <td rowspan="1" colspan="1">FEV1 81 to 90% of baseline and/or FEF25-75%&#x000a0;&#x02264; 75% of baseline</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">BOS 1</td>
                <td rowspan="1" colspan="1">Mild BO</td>
                <td rowspan="1" colspan="1">FEV1 66% to 80% of baseline</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">BOS 2</td>
                <td rowspan="1" colspan="1">Moderate BO</td>
                <td rowspan="1" colspan="1">FEV1 51 % to 65% of baseline&#x000a0;</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">BOS 3</td>
                <td rowspan="1" colspan="1">Severe BO</td>
                <td rowspan="1" colspan="1">FEV1 &#x02264; 50% of baseline&#x000a0; &#x000a0; &#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Each stage is subdivided into a and b, where a is without histologic documentation of OB, and b is with histologic documentation of OB.&#x000a0;</p>
      </sec>
      <sec id="article-18642.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of bronchiolitis obliterans depends on the underlying pathology.&#x000a0;Some patients achieve complete improvement; however, those with constrictive disease generally demonstrate a more progressive course,&#x000a0;but at present,&#x000a0;there&#x000a0;is insufficient research to provide a statistical correlation. Lung function often deteriorates over time, so patients will usually need to have repeated lung testing throughout their lives. Progressive disease may require supplemental oxygen or mechanical ventilation in very severe cases.&#x000a0;The&#x000a0;worst&#x000a0;cases may require a lung transplant.<xref ref-type="bibr" rid="article-18642.r11">[11]</xref></p>
      </sec>
      <sec id="article-18642.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with&#x000a0;bronchiolitis obliterans&#x000a0;demonstrate&#x000a0;an increased risk of developing lung infections, including bronchitis and&#x000a0;pneumonia. With&#x000a0;bronchiolitis obliterans, these infections are more likely to become severe, resulting in baseline respiratory symptoms&#x000a0;that are substantially worse than persons who do not have this condition.</p>
      </sec>
      <sec id="article-18642.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Patients need to be counseled regarding medication and therapy adherence, to remain active within the limitations of their respiratory limitations, and to return for lung function testing to monitor for disease progression.</p>
      </sec>
      <sec id="article-18642.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of bronchiolitis obliterans is done with a multidisciplinary team that includes a transplant surgeon, pulmonologist, pathologist, radiologist, internist, nurse practitioner, and a pharmacist. The condition has no cure and is progressive. Most patients need some type of medical therapy to&#x000a0;relieve the symptoms. Retransplant is an&#x000a0;option but&#x000a0;most patients are frail and not&#x000a0;fit for surgery. Patients managed with&#x000a0;corticosteroids and cytotoxic&#x000a0;drugs also develop&#x000a0;a whole host of adverse&#x000a0;drug&#x000a0;reactions.</p>
        <p>The overall outlook for most patients is guarded and the quality of life is poor. Most patients do die prematurely from respiratory failure. <xref ref-type="bibr" rid="article-18642.r6">[6]</xref><xref ref-type="bibr" rid="article-18642.r12">[12]</xref><xref ref-type="bibr" rid="article-18642.r13">[13]</xref></p>
      </sec>
      <sec id="article-18642.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18642&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18642">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/bronchiolitis-obliterans/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18642">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18642/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18642">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18642.s16">
        <title>References</title>
        <ref id="article-18642.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavaliunaite</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Diagnosing and managing bronchiolitis obliterans in children.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2019</year>
            <month>May</month>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>481</fpage>
            <page-range>481-488</page-range>
            <pub-id pub-id-type="pmid">30798629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohanakumar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaza</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of antibodies to lung self-antigens (K&#x003b1;1 tubulin and collagen V) and donor specific antibodies to HLA in lung transplant recipients and implications for lung transplant outcomes: Single center experience.</article-title>
            <source>Transpl Immunol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>54</volume>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">30794945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shabrawishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qanash</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Bronchiolitis Obliterans After Cefuroxime-Induced Stevens-Johnson Syndrome.</article-title>
            <source>Am J Case Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>09</day>
            <volume>20</volume>
            <fpage>171</fpage>
            <page-range>171-174</page-range>
            <pub-id pub-id-type="pmid">30737366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chambers</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Bronchiolitis obliterans syndrome 'endotypes' in haematopoietic stem cell transplantation.</article-title>
            <source>Respirology</source>
            <year>2019</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5</issue>
            <fpage>408</fpage>
            <page-range>408-409</page-range>
            <pub-id pub-id-type="pmid">30730090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colom</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Teper</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Post-infectious bronchiolitis obliterans.</article-title>
            <source>Pediatr Pulmonol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>212</fpage>
            <page-range>212-219</page-range>
            <pub-id pub-id-type="pmid">30548423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bondeelle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bergeron</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation.</article-title>
            <source>Expert Rev Respir Med</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>105</fpage>
            <page-range>105-119</page-range>
            <pub-id pub-id-type="pmid">30523731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wieruszewski</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Herasevich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gajic</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Respiratory failure in the hematopoietic stem cell transplant recipient.</article-title>
            <source>World J Crit Care Med</source>
            <year>2018</year>
            <month>Oct</month>
            <day>16</day>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>62</fpage>
            <page-range>62-72</page-range>
            <pub-id pub-id-type="pmid">30370228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Jan</month>
            <day>26</day>
            <volume>129</volume>
            <issue>4</issue>
            <fpage>448</fpage>
            <page-range>448-455</page-range>
            <pub-id pub-id-type="pmid">27856461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Storer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Jagasia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Pidala</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crothers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pusic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.</article-title>
            <source>Ann Am Thorac Soc</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>1932</fpage>
            <page-range>1932-1939</page-range>
            <pub-id pub-id-type="pmid">27513368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheth</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Belperio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fishbein</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kazerooni</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lagstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Sisson</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Sundaram</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zisman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Utility of Transbronchial vs&#x000a0;Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease.</article-title>
            <source>Chest</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>151</volume>
            <issue>2</issue>
            <fpage>389</fpage>
            <page-range>389-399</page-range>
            <pub-id pub-id-type="pmid">27729263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Analysis of clinical characteristics of 21 cases of acute fibrinous and organizing pneumonia].</article-title>
            <source>Zhonghua Jie He He Hu Xi Za Zhi</source>
            <year>2020</year>
            <month>Aug</month>
            <day>12</day>
            <volume>43</volume>
            <issue>8</issue>
            <fpage>670</fpage>
            <page-range>670-676</page-range>
            <pub-id pub-id-type="pmid">32727179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ren</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kaleekal</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Graviss</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Goodarzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agboli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Loebe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scheinin</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bruckner</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Retransplantation Outcomes at a Large Lung Transplantation Program.</article-title>
            <source>Transplant Direct</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>e404</fpage>
            <pub-id pub-id-type="pmid">30534595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18642.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hakim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Pavletic</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>383</fpage>
            <page-range>383-392</page-range>
            <pub-id pub-id-type="pmid">30038355</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
